[Abstract Only] Randomized Trial: Triple Therapy Effective for the Treatment of Cystic Fibrosis

1 Nov, 2019 | 10:22h | UTC

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele – New England Journal of Medicine (link to abstract – $ for full-text)

Editorial: Realizing the Dream of Molecularly Targeted Therapies for Cystic Fibrosis (free)

Related Research: Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Commentary: Three-drug combo improves lung function in most common genetic form of cystic fibrosis – UT Southwestern Medical Center (free)

 

Related Commentary on Twitter

Join our WhatsApp group

Free Updates in All Specialties!

A daily update on the latest medical news, practice-changing trials and guidelines

Stay Updated in Your Specialty
No spam, just news
Unsubscribe with one click

 

Daily

 

Weekly or Less Often 
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •